Clinical Trial Update: Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating adjuvant interferon-alpha in hepatocellular carcinoma patients after curative surgery who have low miR-26 expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Interferon-alpha (interferon alpha)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN